121 230

Cited 1 times in

Management of BCG Failures in Non-Muscle-Invasive Bladder Cancer

Authors
 Kyung Seok Han  ;  Sung Joon Hong 
Citation
 KOREAN JOURNAL OF UROLOGY, Vol.50(11) : 1037-1047, 2009 
Journal Title
 KOREAN JOURNAL OF UROLOGY 
ISSN
 2005-6737 
Issue Date
2009
Keywords
Urinary bladder neoplasms ; Bacillus Calmette-Guerin ; Treatment failure ; Cystectomy ; Intravesical therapy
Abstract
PURPOSE: Bacillus Calmette-Guerin (BCG) intravesical therapy is the standard treatment in high-risk patients with non-muscle-invasive bladder cancer, but a significant number of patients experience recurrence after BCG therapy. Although several treatment options are available for recurrence after BCG therapy, the optimal treatment strategy is still controversial. We reviewed current and promising treatment options after BCG failure. MATERIALS AND METHODS: search of published literature using PubMed and meeting abstracts was performed. RESULTS: BCG failures are further subdefined as BCG refractory, BCG resistant, BCG relapsing, and BCG intolerance. Several predictors for BCG response have been studied, but prediction or stratification before therapy seems to be difficult in clinical practice. Novel biomarkers associated with immunologic mechanisms appear to be promising to predict BCG failure. Radical cystectomy is the standard treatment for BCG-refractory disease, but the timing of cystectomy is controversial. BCG maintenance or combination with interferon-alpha is a promising therapy for BCG resistance or relapse. Some salvage therapies or device-assisted instillations have been also promising, but the efficacy and safety of these novel therapies should be confirmed by large prospective studies before their clinical use in BCG failure. CONCLUSIONS: Patients with BCG failure are not a homogeneous group and need to be stratified. Radical cystectomy should be performed without delay in patients with BCG-refractory status, but salvage intravesical therapies may be an alternative in cases without true refractory status. Although BCG and interferon intravesical therapy is promising, more efficient salvage therapy after BCG failure is required.
Files in This Item:
T200904577.pdf Download
DOI
10.4111/kju.2009.50.11.1037
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Han, Kyung Seok(한경석)
Hong, Sung Joon(홍성준) ORCID logo https://orcid.org/0000-0001-9869-065X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/105476
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse